- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03146936
Swiss Primary Sclerosing Cholangitis Cohort Study
April 19, 2022 updated by: Fondazione Epatocentro Ticino
Research project in which biological material is sampled and health-related personal data is further used and collected.
Coded data are used.
Study Overview
Status
Recruiting
Conditions
Detailed Description
The investigators wish to collect high quality prospective data on a rare disease in order to elucidate epidemiology, natural history, response to treatment and outcome.
In addition, a biobank allows addressing specific scientific issues on a variety of open questions.
The cohort will provide a platform for carrying out scientific research projects on PSC.
In addition, the cohort will allow collaborations with reference networks on PSC abroad
Study Type
Observational
Enrollment (Anticipated)
120
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Benedetta Terziroli Beretta-Piccoli, MD
- Phone Number: Terziroli Beretta-Piccoli
- Email: benedetta.terziroli@hin.ch
Study Locations
-
-
-
Basel, Switzerland, 4031
- Recruiting
- Universitäts-Kinderspital beider Basel UKBB, Gastroenterologie&Ernährung
-
Basel, Switzerland, 4031
- Recruiting
- Gastroenterologie und Hepatologie Clarunis - Universitäres Bauchzentrum Universitätsspital Basel
-
Contact:
- Christine Bernsmeier, PD Dr. med. Dr. phil.
- Phone Number: +41 61 777 7400
- Email: Christine.Bernsmeier@clarunis.ch
-
Bern, Switzerland, 3010
- Recruiting
- Inselspital
-
Contact:
- Maria Gabriela Delgado, MD
- Phone Number: +4131 632 09 00
- Email: mariagabriela.delgado@insel.ch
-
Bern, Switzerland, 3010
- Recruiting
- Kinderklinik, INSELSpital, Universität Bern, Pädiatrische Gastroenterologie, Hepatologie und Ernährung
-
Chur, Switzerland, 7000
- Recruiting
- Kantonsspital Graubünden, Departement für Kinder- und Jugendmedizin
-
Geneve, Switzerland, 1205
- Recruiting
- Hôpitaux Universitaires de Genève, Centre Suisse des Maladies du foie de l'Enfant- Département de l'Enfant et de l'Adolescent
-
Geneve, Switzerland, 1205
- Recruiting
- Hôpitaux Universitaires de Genève, Service de Gastroentérologie & Hépatologie, Département des Spécialités
-
Lausanne, Switzerland, 1011
- Recruiting
- CHUV Département femme-mère-enfant
-
Contact:
- Andreas Nydegger, MD
- Phone Number: +41 21 314 11 11
- Email: andreas.nydegger@chuv.ch
-
Liestal, Switzerland, 4410
- Recruiting
- Kantonsspital Baselland
-
Lucerne, Switzerland, 6000
- Recruiting
- Kinderspital Luzern LUKS, Pädiatrische Gastroenterologie
-
Lugano, Switzerland, 6900
- Recruiting
- EOC Ospedale Regionale di Lugano - Italiano
-
Contact:
- Andrea De Gottardi, Prof Dr. med
- Phone Number: +41 91 811 7637
- Email: Andrea.DeGottardi@eoc.ch
-
Sankt Gallen, Switzerland, 9006
- Recruiting
- Ostschweizer Kinderspital
-
Sankt Gallen, Switzerland, 9007
- Recruiting
- Kantonsspital St.Gallen
-
Winterthur, Switzerland, 8400
- Recruiting
- Kantonsspital Winterthur
-
Contact:
- Björn Becker, MD
- Phone Number: +41 052 266 21 21
- Email: bjoern.becker@ksw.ch
-
Winterthur, Switzerland, 8400
- Recruiting
- Pädiatrische Gastroenterologie Departement Kinder- und Jugendmedizin Kantonsspital Winterthur
-
Contact:
- Klaas Heyland, Dr. med.
- Phone Number: +41 522663452
- Email: klaas.heyland@ksw.ch
-
Zurich, Switzerland, 8091
- Recruiting
- Universitatsspital Zurich
-
Zurich, Switzerland, 8032
- Recruiting
- Universitäts-Kinderspital Zürich - Eleonorenstiftung
-
-
Ticino
-
Lugano, Ticino, Switzerland, 6900
- Recruiting
- Fondazione Epatocentro Ticino
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
PSC patients living in Switzerland of any age Patients diagnosed with PSC according to established criteria (European Association for the Study of the Liver.
EASL Clinical Practice Guidelines: management of cholestatic liver diseases).
Only patients living in Switzerland are enrolled.
Enrollment of minors is possible upon consent of legal guardian
Description
Inclusion Criteria:
- Patients diagnosed with PSC according to established criteria (European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases) of any age. Patients not fulfilling such criteria but still diagnosed with PSC in a hepatology referral centre can be included
- patients living in Switzerland
Exclusion Criteria:
- N/A
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease course
Time Frame: 3 years
|
Observing disease course
|
3 years
|
Disease features
Time Frame: 3 years
|
Observing disease features in Swiss population and see if they are similar to other countries'
|
3 years
|
Response to treatment
Time Frame: 3 years
|
Observing response to treatment
|
3 years
|
Overall survival
Time Frame: 3 years
|
Observing overall survival
|
3 years
|
Transplantation-free survival rate
Time Frame: 3 years
|
Observing transplantation-free survival rate
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 28, 2017
Primary Completion (Anticipated)
December 31, 2022
Study Completion (Anticipated)
December 31, 2022
Study Registration Dates
First Submitted
May 8, 2017
First Submitted That Met QC Criteria
May 8, 2017
First Posted (Actual)
May 10, 2017
Study Record Updates
Last Update Posted (Actual)
April 20, 2022
Last Update Submitted That Met QC Criteria
April 19, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SASL40 - Swiss PSC Cohort
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cholangitis, Sclerosing
-
Medical University of WarsawNational Science Centre, PolandRecruitingPrimary Sclerosing Cholangitis (PSC)Poland
-
Mayo ClinicActive, not recruiting
-
Cascade Pharmaceuticals, IncCovanceCompletedPrimary Sclerosing Cholangitis (PSC)United States
-
Brigham and Women's HospitalCompletedSclerosing CholangitisUnited States
-
RenJi HospitalRecruitingPrimary Sclerosing Cholangitis | IgG4-related Sclerosing CholangitisChina
-
HighTide Biopharma Pty LtdCompletedPrimary Sclerosing Cholangitis (PSC)United States, Canada
-
Intercept PharmaceuticalsCompletedPrimary Sclerosing Cholangitis (PSC)United States, Italy
-
Mirum Pharmaceuticals, Inc.CompletedPrimary Sclerosing Cholangitis (PSC)United States, United Kingdom, Canada
-
Mayo ClinicCompletedPrimary Sclerosing Cholangitis (PSC)United States
-
Gilead SciencesCompletedPrimary Sclerosing Cholangitis (PSC)United States, Belgium, Canada, Germany, United Kingdom, Italy, Spain, Denmark, Netherlands, Sweden